Latest News and Press Releases

Agomab Therapeutics NV today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares (“ADSs”)

Agomab today announced the pricing of its initial public offering of 12,500,000 ADSs representing 12,500,000 of its common shares.

Agomab today announced the launch of its initial public offering of 12,500,000 ADSs pursuant to a registration statement filed with the SEC.